Navigation Links
Pixantrone Now Available in Europe on a Named-Patient Basis
Date:5/4/2009

Cell Therapeutics and IDIS Partner to Accelerate Patient Access to Pixantrone through Program

SEATTLE, May 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that pixantrone is now available on a named-patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with aggressive non-Hodgkin's lymphoma (NHL) that has either relapsed after standard therapies or is refractory to them. We know of no therapy that has previously been shown to be effective treatment for such patients.

"CTI has worked hard to make pixantrone available in Europe at the prescriber's request as it provides an option for these difficult to treat aggressive NHL patients," noted Craig Philips, President of CTI. "We continue to work toward potential approval of pixantrone at the end of 2009 in the United States and expect to complete the submission of the New Drug Application to the Food & Drug Administration this quarter."

"Our experience with pixantrone has been positive with patients achieving a complete response where such a result was not achievable with other treatments," said Prof. Pier Luigi Zinzani, M.D., Institute of Hematology and Oncology, University of Bologna. "I am pleased that it is now available on a named-patient basis as it has the potential to address a significant unmet need in this heavily pretreated patient population."

A named-patient program is a compassionate use drug supply program under which physicians can legally supply investigational drugs to qualifying patients. Under a named-patient program, investigational drugs can be administered to patients who are suffering from serious illnesses prior to the drug being approved by the European Medicines Evaluation Agency. "Named-patient" distribution refers to the distribution or

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone
2. Top 10 Hospital Technologies: C-Suite Watch List for 2009 and Beyond; Exclusive Insight on Critical Capital Decisions in ECRI Institute White Paper Available for Free Download
3. Photos: ANTHELIOS 60 Sunscreen(1) with CELL-OX SHIELD(TM) Available May 1 Nationwide
4. Free Treatment for Breast Cancer Available in Pennsylvania
5. Aviation Ventilation Expert Available to Speak About Swine Flu Spread on Airplanes
6. Dr. Siegal's Cookie Diet Book by Sanford Siegal, D.O., M.D., Available May 22nd
7. Available for Interviews: Pandemic, Disease Outbreak Expert to Discuss Swine Flu
8. Dr. Siegals Cookie Diet Book by Physician, Author, and Weight-Loss Expert Sanford Siegal, D.O., M.D., Available May 22nd
9. A New, Highly Effective, Non-Narcotic Pain Medication Now Available for Chronic Pain Patients
10. Pork Industry Electronic Statements and Interviews Available
11. Media Advisory: PHR Experts Available to Comment on Torture
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million 2HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2Van Andel Institute Cuts Ribbon on $178 Million Expansion 2Van Andel Institute Cuts Ribbon on $178 Million Expansion 3Van Andel Institute Cuts Ribbon on $178 Million Expansion 4Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 1Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 2Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 3Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 4Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 5Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 6Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 7Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 8Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 9Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 10Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 11Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 12Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 13Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 14Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Idaho AARP Members 51453 15GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas 4718 1GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas 4718 2Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 1Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 2Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 3Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 4